Alnylam Pharmaceuticals Inc., of Cambridge, Mass., reported fourth-quarter and full-year global net product revenues of Onpattro (patisiran) totaling $55.8 million and $166.4 million, respectively. Onpattro, the first RNAi-based therapy to win FDA approval, is indicated for treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis. As of year-end 2019, more than 750 patients worldwide were receiving Onpattro commercially, with more than 1,000 patients worldwide receiving treatment, Alnylam reported. The company also said it has so far observed strong demand for Givlaari (givosiran), another RNAi therapy, approved in late November to treat adults with rare genetic disorder hepatic porphyria. In the first six weeks following approval, there were 13 start forms received. Alnylam reported GAAP net losses of $276.2 million and $866.1 million, respectively, for the fourth quarter and full year, with earnings per share of $2.47 and $8.11, respectively. As of Dec. 31, the company had cash and investments totaling $1.55 billion. Shares of Alnylam (NASDAQ:ALNY) closed Feb. 6 at $121.96, up 37 cents.
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., posted fourth-quarter revenues of $2.17 billion, up 13% over the same period in 2018. Full-year revenues totaled $7.86 billion, up 17% year over year. U.S. net sales of ophthalmology drug Eylea (aflibercept) increased 13% to $1.22 billion and full-year U.S. net sales rose 14% vs. 2018. Global net sales of Dupixent (dupilumab), as recorded by partner Sanofi SA, of Paris, increased 136% to $752 million vs. the fourth quarter of 2018 and increased to $2.32 billion for the full year 2019. Regeneron posted net income of $792 million and GAAP diluted earnings per share (EPS) of $6.93 for the quarter. For the full year, net income was $2.1 billion. As of Dec. 31, the company had cash and marketable securities of $6.5 billion. Shares of Regeneron (NASDAQ:REGN) closed Feb. 6 at $389.85, up $17.69.